SI2523691T1 - Fluranski kompleks - Google Patents

Fluranski kompleks

Info

Publication number
SI2523691T1
SI2523691T1 SI201130352T SI201130352T SI2523691T1 SI 2523691 T1 SI2523691 T1 SI 2523691T1 SI 201130352 T SI201130352 T SI 201130352T SI 201130352 T SI201130352 T SI 201130352T SI 2523691 T1 SI2523691 T1 SI 2523691T1
Authority
SI
Slovenia
Prior art keywords
ether complex
halogenated ether
halogenated
complex
ether
Prior art date
Application number
SI201130352T
Other languages
English (en)
Inventor
Norbert Roewer
Jens Broscheit
Original Assignee
Sapiotec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapiotec Gmbh filed Critical Sapiotec Gmbh
Publication of SI2523691T1 publication Critical patent/SI2523691T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/08Ethers or acetals acyclic, e.g. paraformaldehyde
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
SI201130352T 2010-01-14 2011-01-14 Fluranski kompleks SI2523691T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20100150786 EP2345427A1 (de) 2010-01-14 2010-01-14 Flurankomplex
PCT/EP2011/050428 WO2011086146A1 (de) 2010-01-14 2011-01-14 Flurankomplex
EP11700182.6A EP2523691B1 (de) 2010-01-14 2011-01-14 Flurankomplex

Publications (1)

Publication Number Publication Date
SI2523691T1 true SI2523691T1 (sl) 2015-02-27

Family

ID=42145043

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201130352T SI2523691T1 (sl) 2010-01-14 2011-01-14 Fluranski kompleks

Country Status (16)

Country Link
US (1) US9125953B2 (sl)
EP (2) EP2345427A1 (sl)
JP (1) JP5752710B2 (sl)
KR (1) KR101767283B1 (sl)
CN (1) CN102933235B (sl)
CA (1) CA2787115C (sl)
CY (1) CY1115967T1 (sl)
DK (1) DK2523691T3 (sl)
ES (1) ES2527010T3 (sl)
HR (1) HRP20141273T1 (sl)
PL (1) PL2523691T3 (sl)
PT (1) PT2523691E (sl)
RS (1) RS53714B1 (sl)
SI (1) SI2523691T1 (sl)
SM (1) SMT201400194B (sl)
WO (1) WO2011086146A1 (sl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925274B2 (en) 2012-11-15 2018-03-27 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
CA2893883A1 (en) 2012-12-11 2014-06-19 Sapiotec Gmbh Delphinidin for combating melanoma cells
EP2913050A1 (de) * 2014-02-28 2015-09-02 SapioTec GmbH Verfahren zur Herstellung eines Flurankomplexes
WO2017004010A1 (en) * 2015-06-30 2017-01-05 Perkinelmer Health Sciences, Inc. Chromatography systems with mobile phase generators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3216897A (en) * 1961-11-02 1965-11-09 Air Reduction Injectable anesthetic
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
GB2350297A (en) * 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
CN1116031C (zh) * 1999-08-17 2003-07-30 刘进 静脉注射用乳化吸入全身麻醉药及其制备方法
IN187686B (sl) * 2000-06-21 2002-06-08 Bharat Serums & Vaccines Ltd
CN1424112A (zh) * 2002-12-17 2003-06-18 上海医药工业研究院 难溶性药物的水溶性包合物及其制备方法
US9000048B2 (en) * 2006-11-28 2015-04-07 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
CN102006903A (zh) * 2008-01-22 2011-04-06 维波真尼克斯公司 挥发性麻醉组合物和应用方法

Also Published As

Publication number Publication date
CA2787115A1 (en) 2011-07-21
US9125953B2 (en) 2015-09-08
US20120296077A1 (en) 2012-11-22
EP2523691B1 (de) 2014-10-01
CN102933235A (zh) 2013-02-13
CN102933235B (zh) 2015-11-25
PT2523691E (pt) 2015-01-05
SMT201400194B (it) 2015-03-05
KR101767283B1 (ko) 2017-08-10
DK2523691T3 (en) 2015-01-12
ES2527010T3 (es) 2015-01-19
RS53714B1 (en) 2015-04-30
CY1115967T1 (el) 2017-01-25
KR20120105563A (ko) 2012-09-25
EP2523691A1 (de) 2012-11-21
HRP20141273T1 (hr) 2015-02-27
JP5752710B2 (ja) 2015-07-22
JP2013517254A (ja) 2013-05-16
WO2011086146A1 (de) 2011-07-21
PL2523691T3 (pl) 2015-03-31
CA2787115C (en) 2017-10-24
EP2345427A1 (de) 2011-07-20

Similar Documents

Publication Publication Date Title
DK3342786T3 (en) Anti-dll3-antistof
AP3107A (en) 5-Alkynyl-pyrimidines
EP2546131A4 (en) MOBILE OBJECT
EP2566479A4 (en) AZA-INDAZOLES
EP2640189A4 (en) 3-deutero-pomalidomide
EP2535631A4 (en) PIPE CONNECTION INDICATING SEALING
DK3466977T3 (en) Anti-vla-4-antistoffer
EP2651505A4 (en) ELECTROPORATION-INDUCED ELECTROSENSIBILIZATION
PL2544567T3 (pl) Okucie zatrzaskowe
GB2482066B (en) Imaging
EP2641891A4 (en) PKC ACTIVATOR-
EP2548959A4 (en) FLORIGENIC ACTIVATOR COMPLEX
HK1173368A1 (en) Pigmentation-preventing or-ameliorating agent
GB201017878D0 (en) Mobile tramsactions
PL2640754T3 (pl) Polimery zawierające eter z terminalnym karbinolem
EP2525500A4 (en) RECEIVER
PL2523691T3 (pl) Kompleks fluranowy
PL2521819T3 (pl) Przestrzeń sanitarna
GB201010960D0 (en) Complex
HK1186457A1 (en) Halogenated diethyltoluenediamines
TWM389812U (en) Tube structure
EP2666761A4 (en) HYDROXYTYROSOL ETHERS
AU4937P (en) FlatinsulGL Myoporum insulare
AU4932P (en) FlatwaxpinkGL Chamelaucium uncinatum
AU4822P (en) FlatwaxwhiteGL Chamelaucium uncinatum